The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The limited access to novel therapeutics for sickle cell disease in LMICs
In this video, Mona El Ghamrawy, MBBch, MSc, MD, Cairo University, Cairo, Egypt, briefly discusses the limited access to novel therapeutics for treating sickle cell disease (SCD) in low- and middle-income countries (LMICs). Dr El Ghamrawy hopes that the cost of curative treatment approaches, namely gene therapy, will decrease with time to make these options accessible to patients. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
